Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First European trial for new breast cancer vaccine

20.03.2002


European clinical trials are under way in Denmark and the UK testing a new breast cancer vaccine targeted against the HER-2 growth factor.



HER-2 is overexpressed in about a quarter of all breast cancers and has become a key target for new treatments, such as the monoclonal antibody therapy Herceptin.

But, the development of a vaccine by Danish pharmaceutical company Pharmexa represents an entirely novel treatment paradigm, according to Pharmexa’s manager of preclinical development and immunopharmacology, Dr Dana Leach.


He told a news briefing at the 3rd European Breast Cancer Conference in Barcelona: "The objective of our vaccine is to stimulate the patient’s own immune system and to see whether we can induce it to launch specific killer cells as well as producing HER-2 specific antibodies. This is a phase I/II trial. Our first objective is to test the safety of the vaccine, but we also want to make a preliminary evaluation of the vaccine’s ability to raise an immune response. There are 27 patients with advanced breast cancer in the trial, which should be completed late this year."

HER-2 is a protein that is overexpressed in many tumours. But, because it is also expressed at low levels in some normal tissues, the immune system does not recognise it as foreign and the immune cells, especially helper T cells that initiate the immune response, are simply not around to launch an attack. So, the vaccine – AutoVac – has been designed to help kick-start the immune response by giving the T cells a foreign agent to recognise and react against. The aim is that the immune system then recognises the overexpressed HER-2 in the cancer cells and attacks them, but ignores the normal tissue because that contains only low levels.

Dr Leach said that animal tests had shown that the vaccine produced a specific immune response and there had been no adverse side effects.

The vaccine consists of two small inactive fragments derived from tetanus toxin – the bacterium that causes lockjaw. The researchers included DNA encoding the fragments, into DNA that they had made in the laboratory to code for a portion of the HER-2 molecule. The DNA vaccine is injected and taken up by the cells, which then manufacture the protein, including the inserted tetanus fragments that ‘wake up’ the immune system and help it to respond to HER-2.

Dr Leach said the company was also preparing to start clinical trials in a variation of this approach. Instead of a DNA vaccine that prompts the body’s cells to make the necessary protein, the AutoVac protein will be made beforehand in the laboratory and injected directly as a vaccine into the patient.

"Each approach has potential advantages – DNA is generally believed to be a good way to get a response from cytotoxic T cells, while protein is better at inducing antibody responses," he said. "We have to look at tackling cancer from as many different approaches as possible because different tumours react in different ways. We know that already from the variable responses to chemotherapy, radiotherapy, endocrine treatment and other immunotherapies. But, as we get better at diagnosis and understanding the genetic make-up of tumours it should become possible to make better predictions about which treatment is best for which patient and to combine treatments that work synergistically to boost effectiveness."

Dr Leach said that the success of the drug Herceptin as a treatment had shown that HER-2 was a good target. "Although it is early days yet, any time that you can successfully take a new cancer vaccine into the clinic it is an important and exciting event."

Margaret Willson | alphagalileo

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>